We claim:
1. An isolated polypeptide of SEQ ID NO: 2.
2. An isolated nucleic acid molecule that encodes a Zins5 polypeptide, wherein the nucleic acid molecule is selected from the group consisting of (a) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 3, (b) a nucleic acid molecule encoding the amino acid sequence of SEQ ID NO: 2, and (c) a nucleic acid molecule that remains hybridized following stringent wash conditions to a nucleic acid molecule consisting of a nucleotide sequence, or the complement of a nucleotide sequence, selected from the group consisting of nucleotides 64 to 225, 64 to 228, 67 to 225, 67 to 228, 97 to 225, 97 to 228, and 224 to 321.
3. The isolated nucleic acid molecule of claim 2, consisting of the nucleotide sequence of SEQ ID NO: 1.
4. A vector, comprising the isolated nucleic acid molecule of claim 2.
5. An expression vector, comprising the isolated nucleic acid molecule of claim 2, a transcription promoter, and a transcription terminator, wherein the promoter is operably linked with the nucleic acid molecule, and wherein the nucleic acid molecule is operably linked with the transcription terminator.
6. A recombinant host cell comprising the expression vector of claim 5, wherein the host cell is selected from the group consisting of bacterium, yeast cell, fungal cell, insect cell, avian cell, mammalian cell, and plant cell.
7. A method of using the expression vector of claim 5 to produce Zins5 protein, comprising culturing recombinant host cells that comprise the expression vector and that produce the Zins5 protein.
8. The method of claim 7, further comprising isolating the Zins5 protein from the cultured recombinant host cells.
9. An antibody or antibody fragment that specifically binds with the polypeptide of claim 1.
10. The antibody of claim 9, wherein the antibody is selected from the group consisting of: (a) polyclonal antibody, (b) murine monoclonal antibody, (c) humanized antibody derived from (b), and (d) human monoclonal antibody.
11. A method of detecting the presence of Zins5 gene expression in a biological samples comprising:
(a) contacting a Zins5 nucleic acid probe under hybridizing conditions with either (i) test RNA molecules isolated from the biological sample, or (ii) nucleic acid molecules synthesized from the isolated RNA molecules, wherein the probe consists of a nucleotide sequence comprising a portion of the nucleotide sequence of the nucleic acid molecule of claim 9, or complements thereof, and
(b) detecting the formation of hybrids of the nucleic acid probe and either the test RNA molecules or the synthesized nucleic acid molecules,
wherein the presence of the hybrids indicates the presence of Zins5 RNA in the biological sample,
or,
(a) contacting the biological sample with an antibody, or an antibody fragment, which specifically binds with a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2, wherein the contacting is performed under conditions that allow the binding of the antibody or antibody fragment to the biological sample, and
(b) detecting any of the bound antibody or bound antibody fragment.
12. A composition, comprising a carrier and the polypeptide of claim 1.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A modified zeolite catalyst with improved acidity and porosity, useful for the conversion of paraffins, olefins and aromatics in a mixed feedstock into isoparaffins, said catalyst comprising noble metal incorporated mordenite zeolite based catalyst comprising:
Zeolite:
in the range of 59-60 wt %;
Pseudo extrude:
in the range of 39-40 wt %;
Pt:
in the range of 0.1-1.0 wt %;
Pd:
in the range of 0-1.0 wt %;
and said catalyst has the following characteristics:
SiAl
in the range of 16-80
BET surface area (m2g)
in the range of 200-350
Micropore area (m2g)
in the range of 155-250
External pore area (m2g)
in the range of 90-135
Pore volume (ccg)
in the range of 0.30-0.50
Acidity (m \xb7 molg \xb7 catal)
in the range of 1.40-1.60
Strong (>120 kJmol)
in the range of 0.40-0.60
Medium(120-80 kJmol)
in the range of 0.45-0.50
Weak(<80 kJmol)
in the range of 0.40-0.60
Pt dispersion (%)
in the range of 60-80.
2. The modified catalyst of claim 1, further defined as comprising:
Zeolite:
59.8 wt %
Pseudo extrude:
39.7 wt %
Pt:
\u20020.3 wt %
Pd:
\u2002\u20090.2 wt %.
3. The modified catalyst of claim 1, wherein said catalyst has the following characteristics:
SiAl
39
BET surface area (m2g)
347
Micropore area (m2g)
248
External pore area (m2g)
99
Pore volume (ccg)
0.4734
Acidity (m \xb7 molg \xb7 catal)
1.48
Strong (>120 kJmol)
0.58
Medium(120-80 kJmol)
0.49
Weak(<80 kJmol)
0.41
Pt dispersion (%)
78.